<li>axitinib<p>pravastatin increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bezafibrate<p>bezafibrate, pravastatin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of rhabdomyolysis.</p></li><li>boceprevir<p>boceprevir increases levels of pravastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bosutinib<p>bosutinib increases levels of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>carbamazepine<p>carbamazepine increases toxicity of pravastatin by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>caspofungin<p>caspofungin increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>cholestyramine<p>cholestyramine decreases levels of pravastatin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>clarithromycin<p>clarithromycin increases levels of pravastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for myopathy; do not exceed pravastatin dose of 40 mg/day when coadministered with clarithromycin .<span><br><br></span>clarithromycin increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>clotrimazole<p>clotrimazole increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>crizotinib<p>crizotinib increases levels of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of pravastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>daclatasvir will increase the level or effect of pravastatin by  Other (see comment). Use Caution/Monitor. Daclatasvir inhibits OATP1B1, OATP1B3, and BCRP. Caution if coadministered with drugs that are substrates of these transporters. Monitor for HMG-CoA reductase inhibitor associated adverse events (eg, myopathy).</p></li><li>daclizumab<p>daclizumab, pravastatin. Other (see comment). Use Caution/Monitor. 
Comment: Caution should be used if hepatotoxic drugs are coadministered, including nonprescription drugs. Both drugs reported to cause autoimmune hepatitis.</p></li><li>daptomycin<p>pravastatin, daptomycin.
Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Coadministration of daptomycin with HMG-CoA reductase inhibitors may increase CPK levels and risk for myopathy; consider temporary suspension of HMG-CoA reductase inhibitors during daptomycin therapy.</p></li><li>darunavir<p>darunavir increases levels of pravastatin by unknown mechanism. Use Caution/Monitor.</p></li><li>digoxin<p>digoxin increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>eliglustat<p>eliglustat increases effects of pravastatin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.</p></li><li>erythromycin base<p>erythromycin base increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>erythromycin stearate<p>erythromycin stearate increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>flibanserin<p>pravastatin will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.</p></li><li>glyburide<p>glyburide increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>indinavir<p>indinavir increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>ivacaftor<p>pravastatin increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .</p></li><li>ketoconazole<p>ketoconazole increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>lanthanum carbonate<p>lanthanum carbonate decreases levels of pravastatin by cation binding in GI tract. Use Caution/Monitor. Administer statin at least 2 hr before or 2 hr after lanthanum. Monitor serum concentrations.</p></li><li>lomitapide<p>pravastatin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.<span><br><br></span>lomitapide increases levels of pravastatin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide.</p></li><li>mesterolone<p>mesterolone increases toxicity of pravastatin by decreasing metabolism. Use Caution/Monitor. Risk of rhabdomyolysis (theoretical interaction based on case reports of combination of danazol and &gt;20 mg/day lovastatin).</p></li><li>metyrapone<p>metyrapone increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>mifepristone<p>mifepristone increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>mipomersen<p>mipomersen increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs; OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>nelfinavir<p>nelfinavir increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of pravastatin by  Other (see comment). Use Caution/Monitor. Paritaprevir inhibits OATP1B1, OATP1B3, and BCRP. Ritonavir inhibits BCRP. Caution if coadministered with drugs that are substrates of these transporters.<span><br><br></span>ombitasvir/paritaprevir/ritonavir will increase the level or effect of pravastatin by  decreasing hepatic clearance. Modify Therapy/Monitor Closely. Maximum daily dose of pravastatin should be limited to 40 mg/day.<span><br><br></span>ombitasvir/paritaprevir/ritonavir will increase the level or effect of pravastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Paritaprevir and ritonavir inhibit P-gp. Caution if coadministered with P-gp substrates.</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of pravastatin by  decreasing hepatic clearance. Modify Therapy/Monitor Closely. Maximum daily dose of pravastatin should be limited to 40 mg/day<span><br><br></span>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>paclitaxel<p>paclitaxel increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>pazopanib<p>pazopanib increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>pioglitazone<p>pioglitazone increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>ponatinib<p>ponatinib increases levels of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>ponatinib increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>ranolazine<p>ranolazine increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>repaglinide<p>repaglinide increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>rifampin<p>rifampin increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>ritonavir<p>ritonavir increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>rosiglitazone<p>rosiglitazone increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>sacubitril/valsartan<p>sacubitril/valsartan increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.<span><br><br></span>pravastatin will increase the level or effect of sacubitril/valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>saquinavir<p>saquinavir increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>sildenafil<p>sildenafil increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>simeprevir<p>simeprevir increases levels of pravastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Simeprevir inhibits OATP1B1 and/or CYP3A4; when coadministered with simeprevir, titrate pravastatin to lowest necessary dose and monitor.</p></li><li>sofosbuvir/velpatasvir<p>sofosbuvir/velpatasvir increases levels of pravastatin by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Velpatasvir is an inhibitor of OATP1B1, OATP1B3, and OATP2B1 transporters. Coadministration may increase systemic exposure of drugs that are substrates of these transporters. Coadministration may significantly increase pravastatin serum concentration, which is associated with increased risk of myopathy, including rhabdomyolysis.</p></li><li>tacrolimus<p>tacrolimus increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>telithromycin<p>telithromycin increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>telmisartan<p>telmisartan increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>valsartan<p>pravastatin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure<span><br><br></span>valsartan increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>vemurafenib<p>vemurafenib increases levels of pravastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li>